ClinicalTrials.gg
WithdrawnNCT01635621Updated Oct 30, 2012

A Phase II Study to Assess the Efficacy and Safety of Olokizumab in Patients With Crohn's Disease

A Phase 2 interventional study of Olokizumab (OKZ) and Placebo in Crohn's Disease, sponsored by UCB BIOSCIENCES GmbH. Withdrawn. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2012-10-30.

Sponsored by UCB BIOSCIENCES GmbH (part of UCB S.A.) · Phase 2, Interventional, and Treatment

Why this study was withdrawn
Study was withdrawn due to delay in timelines. There were no safety concerns regarding the study or the compound in the decision to withdraw the trial.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies in Crohn Disease by UCB S.A. — none open to participants now, none under way, none of them phase 3. Crohn Disease · UCB S.A..

Enrollment
21st of 24
0 · median 92
Started
2012
the only one that year
Phase 2
6 of 28
none open now
Registered
22nd of 28
by date

Among the 28 studies in Crohn Disease by UCB S.A., this one is the 21st largest by enrollment of the 24 interventional ones that give a count, is the only one that started in 2012, is one of 6 in phase 2, and was the 22nd registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

None of the 28 studies in Crohn Disease by UCB S.A. is open now. The open studies under Crohn Disease, anywhere →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 28 studies in Crohn Disease by UCB S.A. as a file.
02

Study summary

The primary purpose of this multi-centre, double blind-study is to evaluate the clinical response of patients with moderate to severe Cohn's Disease (CD) following treatment with different doses and dose regimens of Olokizumab, relative to placebo.

03

Conditions studied

  • Crohn's Disease

Browse trials for

Keywords

  • Olokizumab
  • OKZ
  • CDP6038
  • Crohn's Disease
  • CDAI
  • IBDQ
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is male or female, 18 to 65 years of age at Screening
  • Diagnosis of CD (colonic localization) confirmed (at least 12 weeks prior to Screening) by either radiological or endoscopic evidence and/or histological examination
  • Colonoscopy performed prior to first study medication administration (Week 0) with evidence of active CD and presence of ulceration but with no clinical suspicion of dysplasia or (colonoscopy to be performed after has been received, and all other Screening assessments have been completed)
  • Moderately to severely active CD (CDAI score: 220 to 450, inclusive) at Baseline
  • Female subjects must be either for at least 1 year, surgically incapable of childbearing, or effectively practicing an acceptable method of (either oral/ parenteral /implantable hormonal contraceptives, intrauterine device or barrier and spermicide)

Exclusion criteria

Exclusion Criteria:

  • Subject has a diagnosis of Ulcerative Colitis or Indeterminant Colitis as determined by the investigator
  • Subject has obstructive strictures with clinical evidence of partial or complete obstruction
  • Subject has an active fistula (fistula secreting spontaneously or by gentle pressure)
  • Subject has a history of diverticulitis or symptomatic diverticulosis
  • Subject has any prior exposure to anti-IL-6 agents (eg, Tocilizumab)
  • Female subjects who are breastfeeding, pregnant, or plan to become pregnant during the study or within 24 weeks following the last dose of the study drug
  • Subject has a high risk of infection (eg, subjects with leg ulcers, indwelling urinary catheter, persistent or recurrent chest infections, and subjects who are permanently bedridden or wheelchair bound)
  • Subject has a concurrent or a history of malignancy. Subjects who have been successfully treated and who have remained malignancy-free for at least 5 years prior to Screening may be included
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    OKZ 120 mg

    Drug: Olokizumab (OKZ)

  • Experimental
    OKZ 240 mg

    Drug: Olokizumab (OKZ)

  • Experimental
    OKZ 120 mg with 480 mg loading dose at Week 0

    Drug: Olokizumab (OKZ)

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Subjects will receive one of the following treatment regimens as subcutaneous injection solution on Weeks 0, 2, 4, 6, 8, 10, 12 and 14 of the Treatment Period: * OKZ 120 mg every 2 weeks * OKZ 240 mg every 2 weeks * OKZ 120 mg every 2 weeks, with a loading dose of OKZ 480 mg at Week 0 1.6 mL of OKZ drug substance presented in a glass vial with a 1.2 mL extractable volume at a concentration of 100 mg/mL in the formulation buffer, containing 25 mM sodium citrate, 90 mM sodium chloride, 0.02 % (weight/volume) polysorbate 80, pH 6.0.

    Also known as: CDP6038

  • DrugPlacebo

    Subjects will receive Placebo every 2 weeks as a subcutaneous injection solution (0.9% sodium chloride preservative-free for injection) on Weeks 0, 2, 4, 6, 8, 10, 12 and 14 of the Treatment Period.

06

What researchers measure

Primary outcomes

  1. Percentage of subjects with clinical response or remission as measured by the Crohn's Disease Activity Index (CDAI) at Week 8

    Time frame: Week 8

Secondary outcomes

  1. Percentage of subjects with clinical response as measured by the Crohn's Disease Activity Index (CDAI) at Week 16

    Time frame: Week 16

  2. Percentage of subjects with clinical remission as measured by the Crohn's Disease Activity Index (CDAI) at Week 16

    Time frame: Week 16

  3. Change from Baseline in the Crohn's Disease Activity Index (CDAI) to Week 16

    Time frame: From Baseline to Week 16

  4. Change from Baseline in the Inflammatory Bowel Disease Questionnaire (IBDQ) total score at Week 16

    Time frame: From Baseline to Week 16

  5. Percentage of subjects with Inflammatory Bowel Disease Questionnaire (IBDQ) response at Week 16

    Time frame: Week 16

  6. Percentage of subjects in Inflammatory Bowel Disease Questionnaire (IBDQ) remission at Week 16

    Time frame: Week 16

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2012, a primary completion of Aug 2013 and a completion of Aug 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2012
First posted
Jul 9, 2012
Start
Jun 2012
Primary completionEst.
Aug 2013
CompletionEst.
Aug 2013
Last update
Oct 30, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 30, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01635621
Responsible party
Sponsor
First posted
Jul 9, 2012
Start date
Jun 2012
Primary completion
Aug 2013 (estimated)
Completion
Aug 2013 (estimated)
Last update
Oct 30, 2012

Study contacts

UCB Clinical Trial Call Center
study director · +1 877 822 9493 (UCB)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olokizumab

Start the discussion